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Summary
Asparaginase (ASNase) is an important anti-leukaemic drug in the treat-
ment of childhood acute lymphoblastic leukaemia (ALL) and non-Hodgkin
lymphoma (NHL). A substantial proportion of patients develop hypersensi-
tivity reactions with anti-ASNase neutralising antibodies, resulting in aller-
gic reactions or silent inactivation (SI), and characterised by inactivation
and rapid clearance of ASNase. We report results of a prospective, real-time
therapeutic drug monitoring of pegylated Escherichia coli (PEG-)ASNase
and Erwinia ASNase in children treated for ALL and NHL in Belgium.
Erwinia ASNase was given as second-line after hypersensitivity to PEG-
ASNase. In total, 286 children were enrolled in the PEG-ASNase cohort.
Allergy was seen in 112% and SI in 52% of patients. Of the 42 patients
treated with Erwinia ASNase, 71% experienced allergy and 24% SI. The
median trough PEG-ASNase activity was high in all patients without hyper-
sensitivity. After Erwinia administration significantly more day 3 samples
had activities <100 IU/l (625% vs. 10% at day 2 (D2)). The median D2
activity was significantly higher for intramuscular (IM; 347 IU/l) than for
intravenous Erwinia administrations (159 IU/l). This prospective, multicen-
tre study shows that monitoring of ASNase activity during treatment of
children with ALL and NHL is feasible and informative. Treatment with
Erwinia ASNase warrants close monitoring and optimally adherence to a 2-
day interval of IM administrations.
Keywords: acute lymphoblastic leukaemia, childhood, asparaginase, allergy,
silent inactivation, therapeutic drug monitoring.
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For several decades, asparaginase (ASNase) has proven to be
a key element in the multidrug chemotherapy regimen for
acute lymphoblastic leukaemia (ALL) and non-Hodgkin lym-
phoma (NHL) in children (Pui et al., 2008; Hunger & Mul-
lighan, 2015). The enzyme hydrolyses extracellular asparagine
into aspartic acid and ammonia, leading to a depletion of
asparagine in the systemic circulation. Lymphoblasts depend
on extracellular asparagine for their growth and consequen-
tially undergo rapid cell death in the absence of asparagine
(Avramis & Panosyan, 2005; Avramis & Tiwari, 2006).
Currently, three ASNase formulations are used in paedi-
atric ALL and NHL protocols. Native Escherichia coli ASNase
and pegylated E. coli ASNase (PEG-ASNase) are derived from
the bacteria E. coli, while the third formulation, Erwinia
ASNase, is produced by the bacteria Erwinia chrysanthemi.
All three preparations have different pharmacodynamics and
immunogenic properties, therefore many contemporary pro-
tocols use PEG-ASNase as the preferred first-line ASNase due
to its lower immunogenicity and longer half-life. Erwinia
ASNase is often used in second-line after hypersensitivity
reactions (HSR) to diminish the risk of cross-reactivity of
antibodies (Pieters et al., 2011; van der Sluis et al., 2016).
A major concern in the treatment with ASNase is failure
to achieve sufficient ASNase activity, due to immune
responses such as allergic reactions and silent inactivation
(SI), the latter referring to the inactivation of the ASNase
product by neutralising antibodies in the absence of any clin-
ical allergic reaction. In patients who develop HSR or neu-
tralising antibodies to ASNase, increased ASNase clearance
was demonstrated leading to subtherapeutic serum levels of
the drug. Importantly, several studies described an inferior
outcome in cases of suboptimal efficacy of this potent anti-
leukaemic drug (Amylon et al., 1999; Avramis et al., 2002;
Pession et al., 2005; Moghrabi et al., 2007). To overcome
inefficient ASNase exposure these patients benefit from
switching ASNase preparations, preferably to a formulation
from another bacterial source (van der Sluis et al., 2016; Sal-
zer et al., 2018).
Recently, it became clear that SI can only be detected by
consecutive monitoring of ASNase levels during therapy. In
the present study, we prospectively monitored ASNase in a
uniformly treated, large Belgian cohort of newly diagnosed
childhood ALL and NHL patients and provide further evi-
dence on the importance of monitoring during treatment.
Patients and methods
Patients and study design
Children (1–18 years) with newly diagnosed ALL and precur-
sor B or T lymphoblastic NHL treated in Belgian depart-
ments for paediatric haematology-oncology were enrolled in
the real-time ASNase monitoring programme (Belgian regis-
tration number: B67020109345).
All patients were treated according to the treatment guide-
lines of the European Organisation for the Research and
Treatment of Cancer Children’s Leukaemia Group (EORTC-
CLG) 58081 study, based on EORTC-protocol 58951 (De
Moerloose et al., 2010; Domenech et al., 2014; Mondelaers
et al., 2017), and received PEG-ASNase in frontline (Table I;
Data S1).
Patients with allergic reactions of Grade ≥ 2 to PEG-
ASNase or SI were switched to Erwinia ASNase. One dose of
PEG-ASNase 2500 IU/m2 was replaced by six doses of
20 000 IU/m2 Erwinia ASNase, given every 2–3 days. For
average risk 2 (AR2)-patients with allergy or SI during main-
tenance, PEG-ASNase (1000 IU/m2) was replaced by two
doses of Erwinia ASNase (25 000 IU/m2/dose) with a dose
interval of 48 h (Table I). PEG-ASNase was given intra-
venously (IV), Erwinia ASNase IV or intramuscularly (IM)
upon preference of the treating physicians.
Serum samples were collected at time points of routine
blood examinations. For PEG-ASNase, samples were collected
before (nadir) and 1 h after (peak) administration (D0), at
day 7  1 (D7) and day 14  1 (D14). Some centres also
collected day 3/4 (D3) and day 10/11 (D10) samples. Sam-
ples to determine trough level Erwinia ASNase activities were
measured before and at 2 (D2) to 3 days (D3) after Erwinia
ASNase (prior to next Erwinia ASNase).
Details on activity measurements are described in the Sup-
porting Information.
Definition of allergy and SI
Clinical allergy to ASNase was defined according to Common
Terminology Criteria for Adverse Events (CTCAE) version
403 criteria (Miller et al., 1981) and graded according to the
Ponte di Legno toxicity working group (PTWG) consensus
(Schmiegelow et al., 2016).
Inactivation of PEG-ASNase was defined as an activity
level of <100 IU/l (at or) before D7 or below lower limit of
quantification (<LLQ) (at or) before D14 after administra-
tion. Inactivation of Erwinia ASNase was present if the level
was <LLQ at D2/D3 after Erwinia ASNase. SI was defined as
inactivation in a patient without symptoms of allergy (Sch-
miegelow et al., 2016; van der Sluis et al., 2016). HSR
included both clinical allergy and SI. Insufficient activity
refers to an activity level of <100 IU/l, rapid clearance of
PEG-ASNase is used if patients have levels of <100 IU/l at
D14, but normal activities in the preceding (D1–D10) and
subsequent measurements.
Statistical analysis
The data were analysed with the Statistical Package for the
Social Sciences (SPSS) software, version 20.0.0.1 (SPSS Inc.,
Chicago, IL, USA) and Sigmaplot version 13.0 for Windows
2013.
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Repeated measurements of the PEG-ASNase activity levels
were evaluated using mixed models analysis of variance with
an unstructured covariance matrix and time point as fixed
effect. We assume that missing data are completely at ran-
dom.
ASNase activity levels are presented as median and ranges,
unless otherwise specified. Mean ASNase activity levels are
used for the mixed models analysis.
Categorical values were compared using Fisher’s exact
tests. Differences in activity levels were tested using the
Kruskal–Wallis ANOVA on ranks. A two-sided P < 005 was
considered statistically significant.
For detailed Methods see Data S1.
Results
Patient characteristics
Between January 2013 and November 2017, 286 consecutive
patients (118 girls and 168 boys) with newly diagnosed ALL
(n = 260) and precursor B or T lymphoblastic NHL (n = 26)
were enrolled in the prospective real-time ASNase monitor-
ing programme and a total of 3777 samples from the patients
were analysed. In the same period, parents of 12 patients
declined participation. Demographic characteristics of the
PEG-ASNase and Erwinia ASNase groups are shown in
Table II. Clinical allergic reactions were seen in 32 (112%)
of the patients treated with PEG-ASNase. The majority were
classified as CTCAE 403 Grade 2 (281%) or 3 (656%) and
688% was severe according to the PTWG criteria. SI was
seen in 15 (52%) patients treated with PEG-ASNase (Figs 1
and 2A). Most allergies occurred after the second (281%) or
third administration (594%). SI was seen after the second
(333%) or the third administration (267%) and in mainte-
nance therapy (40%) (Fig 1). Patients were more at risk for
HSR after an ASNase-free period. Almost all patients who
had a hypersensitivity reaction at the second dose had a
delay for the administration of this dose due to clinical prob-
lems such as infections. The median interval between the two
doses was 225 days in the patients with HSR compared to
14 days in patients without HSR (P < 0001).
In all, 42 of the hypersensitive patients were switched to
Erwinia ASNase. Three (71%) experienced a clinical allergic
reaction, and one (24%) a SI on Erwinia ASNase (Figs 1
and 2B). All three allergic reactions were CTCAE 403 Grade
3 or severe according to the PTWG criteria.
PEG-ASNase activity
After exclusion of trough samples, adequate PEG-ASNase
activity of >100 IU/l was obtained in 977% of the samples
from 286 patients treated with PEG-ASNase 2500 IU/m2 and
in >90% of the samples from 42 AR2-patients treated with
PEG-ASNase 1000 IU/m2 during maintenance therapy. The
median (range) ASNase activity after the first PEG-ASNaseT
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administration was 1254 (704–2027) IU/l (peak sample),
921 (147–1727) IU/l at D7 and median trough level at D14
was 574 (<5–1807) IU/l. After the second administration in
induction patients ASNase activity levels were higher: median
(range) 2091 (<5–5208) IU/l (peak), 1181 (<5–2107) IU/l at
D7 and 666 (<5–1151) IU/l at D14. After PEG-ASNase in re-
induction, the median (range) ASNase activity was
1916 (<5–13 255) IU/l (peak), 1358 (<5–5621) IU/l at D7
and 802 (<5– 3346) IU/l at D14 (Table III; Table SI). After
exclusion of patients with HSR, we measured significantly
higher mean trough levels at D14 after the second
administration in induction and after the administration in
re-induction (Fig 3). In induction no statistically significant
different activity levels were observed according to EORTC-
risk group or corticosteroid (prednisolone/dexamethasone)
used (data not shown).
Evolution of patients with SI or allergy
Table SIII outlines the evolution of ASNase activity during
treatment. Target ASNase activity of ≥100 IU/l was achieved in
all samples until D10/11 after the first PEG-ASNase in
Fig 1. Consort statement for the PEG-ASNase and Erwinia ASNase cohort. HSR, hypersensitivity reaction; SI, silent inactivation; PEG, PEG-
ASNase; ERW, Erwinia ASNase; Native EC, native E. coli ASNase; STOP, discontinuation of ASNase therapy; VHR, very high risk; AR2, average
risk 2. One patient had an allergic reaction to PEG-ASNase and a SI to Erwinia ASNase. #Three patients had an allergic reaction to PEG-ASNase
and to Erwinia ASNase.
V. Mondelaers et al.
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induction. The activity dropped under the level of sufficient
ASNase activity at D14 in six of 243 patients and in two of them
under the LLQ, indicating a possible SI. In one of those two
patients, SI was confirmed after the second administration in
induction, i.e. activity levels <5 IU/l at all time-points. The
other patient with SI at D14 experienced an allergic reaction at
the second dose, as well as one of the remaining four patients
with ASNase activity <100 IU/l at D14. Seven additional
patients had an allergic reaction at the second administration,
three of which with low activity levels, and four with peak activ-
ity levels >100 IU/l. The ASNase activity in one of the latter
patients declined rapidly under the LLQ at D7 and D14 after the
second administration. One of the allergic patients with ade-
quate peak activity was subsequently treated with native E. coli
ASNase and had ASNase activity levels >100 IU/l for the
remainder of the treatment.
After the second dose in induction, 11 patients had an
insufficient ASNase activity at D14, with six patients having
activity levels <5 IU/l. Two patients with a D14 sample
<LLQ and one with a D14 sample of 58 IU/l were not
switched to Erwinia and received a third PEG-dose in late
intensification and SI was confirmed in each of them. One
had a D7 activity of 102 IU/l after the third dose and at D14
was < LLQ. The second one had a high peak (2012 IU/l)
and D3 (1546 IU/l) after the third dose, but rapidly declined
in the D7 and D14 samples to < LLQ. The third patient with
a D14 activity of 58 IU/l after the second dose, had the same
pattern after the third administration (peak: 2187 IU/l; D7
and D10 < LLQ).
Another interesting case was an AR2-patient, in whom the
second PEG-dose in induction was postponed to the delayed
intensification due to a symptomatic sinus sigmoideus
thrombosis. This patient had D10 and D14 activities <LLQ
after the first administration in delayed intensification, but
normal activities after the second (catch up) dose in delayed
intensification (D11: 880 IU/l; D14: 698 IU/l); however, he
presented SI after the subsequent administration during
maintenance (peak: 625 IU/l; D7: 65 IU/l; D14: <5 IU/l).
During maintenance, some of the AR2-patients had nor-
mal activities at D7 of all six blocks, but D14 activities were
<5 IU/l. Probably the 1000 IU/m2 dose was too low due to
rapid clearance.
Erwinia ASNase activity
Erwinia ASNase was given as a second-line after allergic reac-
tion or SI to previous PEG-ASNase administrations. The
median (range) activity 2 days after administration was
321 (14–1195) IU/l and significantly lower 3 days after
administration, at 76 (<5–529) IU/l (P < 0001) (Fig 4A). In
11/33 patients (33%) or 23/238 samples (10%), D2-ASNase
activity was <100 IU/l. None of the samples taken at D2
showed total inactivation of Erwinia ASNase. In contrast, 15/
Fig 2. Frequency of hypersensitivity reactions
(HSR) after administration of PEG-ASNase (A,
N = 286) or Erwinia ASNase (B, N = 42).
[Colour figure can be viewed at wileyonlinelib
rary.com]
Fig 3. ASNase activity at D14 after PEG-ASNase 2500 IU/m2 in
patients without HSR (n = 239). 1A1: first administration in induction,
1A2: second administration in induction; 2A: administration in late
intensification; D14: trough ASNase activity 14 days after the adminis-
tration. [Colour figure can be viewed at wileyonlinelibrary.com]
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20 patients (75%) or 22/32 samples (65%) demonstrated
ASNase activity <100 IU/l at D3.
Interestingly, the median (range) D2 activity was signifi-
cantly higher for IM administrations, at 347 (19–1195) IU/l,
than for IV administrations, at 159 (14–1097) IU/l). A larger
proportion of samples (17/68) and patients (six of 11) in the
IV group did not reach sufficient activity (>100 IU/l) at D2,
compared to six of 165 samples and five of 24 patients in the
IM group (Fig 4B and Table IV).
More than two-thirds of the IV- and IM-treated patients
showed D3 activities of <100 IU/l. One patient in the IM group
had activities <LLQ in all samples, so called Tables IV and SII.
In all, 54% of the IV-treated patients had an activity
exceeding the threshold of 100 IU/l in at least 75% of all
samples, compared to 86% of patients with IM administra-
tions. After limitation to D2 samples, 615% of IV patients
and 905% of IM patients achieved an activity >100 IU/l in
≥75 % of the samples (Table SII).
Discussion
Patients with low ASNase activity during treatment of ALL
have been reported to have increased risk of relapse (Silver-
man et al., 2001; Vrooman et al., 2013). Hence, it is impor-
tant to optimise ASNase therapy by real-time monitoring of
ASNase activity and to react promptly upon SI and insuffi-
cient activities.
We demonstrated that an adequate PEG-ASNase activity
was reached in 977% of the samples from 286 patients after
PEG-ASNase 2500 IU/m2 and in >90% of the samples after
PEG-ASNase 1000 IU/m2 during maintenance therapy. This
is in line with other studies (Appel et al., 2008; Henriksen
et al., 2017). By contrast, studies with native E. coli ASNase
in induction followed by PEG-ASNase in late intensification
or PEG-ASNase in the treatment for relapsed ALL report
higher incidences (20–30%) of patients who did not reach
levels of >100 IU/l (Schrey et al., 2010; Tong et al., 2014).
Consistent with other monitoring projects, we found high
median trough levels with an increase after subsequent PEG-
ASNase administrations. One study described an increase in
mean trough levels after the first two administrations, reach-
ing a steady state from week 4 until week 26. Remarkably
they observed a significant increase in activity levels after the
second last dose (P = 001), although the other treatment
elements did not change (Tong et al., 2014). Similarly, in the
Nordic Society of Pediatric Hematology and Oncology
(NOPHO) 2008 study, ASNase activity initially increased
and reached steady state trough levels after the fifth PEG-
ASNase (Henriksen et al., 2017). More research should be
done to investigate the role of concomitant administered
drugs and alterations in ASNase clearance throughout the
course of the treatment and their impact on ASNase related
side-effects.
Interestingly, one might argue that trough levels after
PEG-ASNase 2500 IU/m2 are too high and might require
dose reductions. However, it should be considered that PEG-
ASNase penetrates poorly in the cerebrospinal fluid (CSF),
and thus a dose-dependent reduction of CSF asparagine
levels is reached, probably due to homeostasis with plasma
asparagine concentrations. Appel et al. (2003) demonstrated
insufficient depletion of asparagine in the CSF after IV PEG-
ASNase 1000 IU/m2, despite complete depletion of plasma
asparagine. This is further illustrated by Avramis et al. (2002)
who reported higher depletion of CSF asparagine levels after
IV PEG-ASNase 2500 IU/m2 compared to the same dose IM
(<02 µmol/l vs. <06 µmol/l).
During the course of the PEG-ASNase treatment, we
observed allergic reactions in 112% and SI in 52% of the
286 patients. If only allergic reactions of Grade ≥ 3 were con-
sidered, the rate was 77%. Similar frequencies of allergic
reactions were reported by August et al. (2013) after IV
(125%) or IM (111%) PEG-ASNase. Pidaparti and Bostrom
(2012) described allergy incidences of 9% in patients receiv-
ing IM PEG-ASNase and of 36% in a very small group of 11
Fig 4. ASNase activity after Erwinia ASNase 20 000 IU/m2 according
to time point after administration (A) and according to the route of
administration on D2 (B). D2: ASNase activity 2 days after the Erwi-
nia administration; D3: ASNase activity 3 days after the Erwinia
administration. IM, intramuscularly; IV, intravenously. [Colour fig-
ure can be viewed at wileyonlinelibrary.com]
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IV-treated patients. In contrast, analysis of 54 280 PEG-
ASNase doses administered to 16 534 patients in six Chil-
dren’s Oncology Group (COG) leukaemia trials (2003–2015)
revealed that Grade ≥ 3 HSR to PEG-ASNase 2500 IU/m2
occurred less frequently with IV infusion than IM injections
(32% vs. 54%, P < 00001). After limiting the analysis to
second and third doses, where, as in our present study, most
of the Grade ≥ 3 allergic reactions occurred, patients were
less likely to have an allergic reaction after IV administra-
tions (50% vs. 101%, P < 00001) (Burke et al., 2018).
Greater allergy (22%) and SI rates (8%) were seen when
patients were treated with PEG-ASNase after an induction
with native E. coli ASNase (Tong et al., 2014).
Longitudinal monitoring of ASNase activity enables pre-
dicting of HSR. In several patients, we found that HSR was
preceded by a rapid clearance or inactivation of ASNase after
the previous dose. This phenomenon underscores the value
of additional sampling allowing a quick detection of inactiv-
ity and a prompt switch to an alternative preparation.
Patients with allergic reactions on or SI to PEG-ASNase
can be switched successfully to Erwinia ASNase (Pieters et al.,
2011). In our present study, 42 patients were switched to
Erwinia ASNase. In contrast to PEG-ASNase lower median
trough activity levels were observed after Erwinia ASNase
administration, namely 321 IU/l at D2 and 76 IU/l at D3,
with significantly more D3 samples <100 IU/l (625% vs. 10%
at D2, P < 0001). This is in agreement with other studies.
Tong et al. (2014) found median trough activity levels of
183 IU/l at D2 and 93 IU/l at D3, with activity levels of
<100 IU/l in 67% of the D3 samples compared to 0% of the
D2 samples after Erwinia ASNase 20 000 IU/m2 IV three-
times per week. In 33% of the patients asparagine was not
completely depleted during Erwinia ASNase therapy. In their
study with Erwinia ASNase 25 000 IU/m2 IV three-times per
week Vrooman et al. (2016) detected mean ASNase activity
levels of 320 IU/l at D2 and 89 IU/l at D3, and activity levels
of <100 IU/l in 27% of patients 48 h post-dose and in 57%
72 h post-dose. In the COG AALL07P2 trial, 2 weeks of Erwi-
nia ASNase at a dose of 25 000 IU/m2 IM three-times weekly
led to higher trough activity levels across all treatment cycles
of 645 IU/l at 48 h and 248 IU/l at 72 h post-dose, and activ-
ity levels of <100 IU/l in 7% of patients at D2 and in 22% at
D3 (Salzer et al., 2013). The IM administrations in our pre-
sent study might be responsible for the higher trough levels
compared to the studies of Tong et al. (2014) and Vrooman
et al. (2016), where IV administrations were given. The influ-
ence of the route of administrations for Erwinia ASNase is
not completely clear in literature. Some studies did not find
differences in activity after IV or IM administrations (Rizzari
et al., 2000; Albertsen et al., 2001), whereas others describe a
difference. In the ALL-Berlin-Frankfurt-M€unster (BFM) 2000
protocol higher median activity was observed after IM admin-
istrations of 10 000 IU/m2 Erwinia ASNase compared to IV,
with a median activity of 151 IU/l and 115 IU/l, respectively
(P = 03); and fewer samples <100 IU/l (IM:15% vs. IV:45%)
at D2 (Schrey et al., 2010). We confirmed the influence of the
route of administration on trough levels. The median D2
activity was significantly higher for IM Erwinia administra-
tions (347 IU/l) than for IV administrations (159 IU/l). In
all, 62% of IV-treated patients and 905% of IM-treated
patients achieved an activity of >100 IU/l in ≥75% of the D2
samples. The large inter- and intra-patient variation of Erwi-
nia ASNase activity in our present study highlights the impor-
tance of therapeutic drug monitoring. Three patients (71%)
developed allergy, and one (24%) SI. Patients with HSR after
Erwinia ASNase had to stop ASNase therapy due to the fact
that there exists no valid switching option for patients already
having a history of hypersensitivity to PEG-ASNase.
Table II. Demographic characteristics of the PEG-ASNase cohort
and Erwinia ASNase cohort.
Characteristic
PEG-ASNase
cohort
Erwinia
ASNase
cohort
Total, n
Patients 286 42
Samples 3356 421
Age at diagnosis, years,
median (range)
51 (11–18.3) 47 (11–16.1)
1 to 2, n 17 2
>2 to 6, n 150 22
>6 to 12, n 69 8
>12 to 18, n 50 10
Gender, n
Female 118 12
Male 168 30
Malignancy, n
ALL 260 38
NHL 26 4
Immunophenotype, n
B cell 209 29
T cell 74 12
ALAL/biphenotypic 3 1
EORTC risk group, n
VLR 29 4
AR1 138 13
AR2 69 15
VHR 50 10
Allergy (PTWG criteria), n 32 3
Mild 1 0
Severe 31 3
Allergy (CTCAE 403 criteria), n 32 3
Grade 1 1 0
Grade 2 9 0
Grade 3 21 3
Grade 4 1 0
Silent inactivation, n 15 1
ALL, acute lymphoblastic leukaemia; NHL, non-Hodgkin lymphoma;
ALAL, acute leukaemia of ambiguous lineage; VLR, very low risk;
AR1 and AR2, average risk 1 and 2; VHR, very high risk; PTWG,
Ponte di Legno Toxicity Working Group.
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In conclusion, our present study shows that a national
therapeutic drug monitoring (TDM) programme with real-
time measurements of ASNase activity is feasible and essen-
tial in ensuring optimal ASNase therapy. ASNase activity
monitoring is indispensable to identify patients with SI,
patients at risk for subsequent HSR and to clarify doubtful
allergic reactions. In the absence of specific complications
related to PEG-ASNase toxicity (pancreatitis, thrombosis), it
is beneficial to administer the second dose on day 14 to
avoid HSR. Our Erwinia ASNase activity monitoring pro-
gramme emphasises the relevance for strict monitoring of
activity levels and adherence to a 2-day interval of IM
administrations. The success of this programme leads to
incorporation of ASNase activity monitoring as a standard of
care in our future childhood ALL protocols in Belgium. The
purpose of future monitoring projects will be to unravel the
influence of high activity levels on toxicity and to investigate
the optimal trough levels to achieve sufficient ASNase activity
balancing toxicity and efficacy.
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